HomeCompareGROUF vs PFE

GROUF vs PFE: Dividend Comparison 2026

GROUF yields 3.93% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $23.7K in total portfolio value· pulled ahead in Year 9
10 years
GROUF
GROUF
● Live price
3.93%
Share price
$12.74
Annual div
$0.50
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.8K
Annual income
$505.35
Full GROUF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GROUF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGROUFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GROUF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GROUF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GROUF
Annual income on $10K today (after 15% tax)
$333.80/yr
After 10yr DRIP, annual income (after tax)
$429.55/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,890.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GROUF + PFE for your $10,000?

GROUF: 50%PFE: 50%
100% PFE50/50100% GROUF
Portfolio after 10yr
$37.7K
Annual income
$13,382.03/yr
Blended yield
35.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GROUF
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
4.0
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GROUF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGROUFPFE
Forward yield3.93%6.13%
Annual dividend / share$0.50$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$25.8K$49.6K
Annual income after 10y$505.35$26,258.71
Total dividends collected$4.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: GROUF vs PFE ($10,000, DRIP)

YearGROUF PortfolioGROUF Income/yrPFE PortfolioPFE Income/yrGap
1$11,093$392.71$9,153$693.39+$1.9KGROUF
2$12,276$407.12$8,593$849.25+$3.7KGROUF
3$13,557$421.09$8,336$1,066.78+$5.2KGROUF
4$14,940$434.58$8,437$1,384.80+$6.5KGROUF
5$16,434$447.60$9,013$1,875.40+$7.4KGROUF
6$18,044$460.14$10,306$2,680.72+$7.7KGROUF
7$19,779$472.18$12,820$4,101.38+$7.0KGROUF
8$21,648$483.73$17,673$6,826.70+$4.0KGROUF
9← crossover$23,658$494.78$27,543$12,591.86$3.9KPFE
10$25,819$505.35$49,560$26,258.71$23.7KPFE

GROUF vs PFE: Complete Analysis 2026

GROUFStock

Grafton Group plc engages in the distribution, retailing, and manufacturing businesses in Ireland, the Netherlands, Finland, and the United Kingdom. Its Distribution segment distributes building and plumbing materials to professional trades people engaged in residential repair, maintenance, and improvement projects, as well as in residential and other new build construction. This segment operates 302 branches primarily under the Selco, MacBlair, and Leyland SDM brands in the United Kingdom; the Chadwicks brand in the Republic of Ireland; the Isero and Polvo brands in the Netherlands; and the IKH brand in Finland. The company's Retailing segment engages in DIY and home improvement business that supplies a range of products, including paints, lighting products, homestyle products, housewares, bathroom products, and kitchens, as well as gardening and Christmas products. This segment operates 35 stores primarily under the Woodie's brand. Its Manufacturing segment manufactures dry mortar for residential and commercial construction projects; and plastics and wooden staircase. Grafton Group plc was founded in 1902 and is headquartered in Dublin, Ireland.

Full GROUF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GROUF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GROUF vs SCHDGROUF vs JEPIGROUF vs OGROUF vs KOGROUF vs MAINGROUF vs JNJGROUF vs MRKGROUF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.